Oregon Health and Science University
OHSU Knight Cancer Institute
Portland, OR
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Not yet accepting
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Accepting patients
TRIlogy-4
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
- T Cell Engager (TCE)
- Trispecific Antibody
- BCMA
- CD3
- GPRC5D
- Randomization
- Phase 3
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Not currently accepting
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
- Proteasome Inhibitor
- Minimal Residual Disease (MRD)
- Randomization
- Phase 2
Accepting patients
LINKER-MM1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (LINKER-MM1)
- Bispecific Antibody
- BCMA
- Phase 1/2
- Has results
Accepting patients
CAMPERR
cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse
- Observational Trial
1 hidden based on your filters.Show All